BioNTech co-founders set to launch new mRNA venture as company sharpens oncology focus [Yahoo! Finance]
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: Yahoo! Finance
BioNTech SE (NASDAQ:BNTX) co-founders Ugur Sahin and Özlem Türeci plan to launch a new independent biotech company focused on next-generation mRNA technologies, the German vaccine developer said on Tuesday, as it intensifies its focus on oncology. BioNTech said it will contribute certain related rights and technologies to the new venture in exchange for a minority stake, with potential milestone payments and royalties. The company stressed that its current pipeline remains unchanged, and it still expects to have 15 ongoing Phase 3 oncology trials by the end of 2026. The co-founders are expected to transition to the new company by year-end. The announcement weighed on BioNTech shares, which fell 21% in early trading. In a separate filing, BioNTech reported a net loss of €1.14 billion ($1.33 billion) for 2025, compared with a loss of €665 million in 2024. Despite continued investment in new drug development, the company ended 2025 with €17.2 billion in cash and financial secu
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech (BNTX) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- BioNTech (BNTX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer [Yahoo! Finance]Yahoo! Finance
- BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung CancerGlobeNewswire
- BioNTech (BNTX) had its "buy" rating reaffirmed by Deutsche Bank Aktiengesellschaft.MarketBeat
BNTX
Earnings
- 3/10/26 - Beat
BNTX
Sec Filings
- 3/25/26 - Form 3
- 3/25/26 - Form 3
- 3/25/26 - Form 3
- BNTX's page on the SEC website